The first dose that a child’s symptoms respond to may not be the best dose to improve function.
Stimulants are generally considered safe medications, with few contraindications to their use.
[An article from the University of Maryland addresses selection of medication for ADHD treatment] A new medication came on the market that appears to be of value to children who do not have a favorable response to stimulants.
Intuniv, a once-daily formulation of guanfacine, was approved by the US Food and Drug Administration (FDA) on September 2, 2009 as the first selective alpha-2A agonist for the treatment of ADHD.
Over 200 well controlled studies have shown that these medications are the safest and most effective psychiatric medications.
Failure to treat ADHD with medications may result in increased risk of substance abuse and decreased white matter volumes in the brain as well as poor academic achievement, low self-esteem, difficulty in a wide range of social situations, over reaction to change and frustrating circumstances and less likelihood of success as adults.